Outcomes of Fecal Microbiota Transplantation for Clostridium difficile Infection in Patients with Inflammatory Bowel Disease

Meighani, Alireza; Benjamin, H.; Bourgi, Kassem; Miller, Nichole; Agboola, John; Ramesh, Mayur

doi:10.1007/s10620-017-4580-4

Cited by 33 publications

(28 citation statements)

References 29 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…[44][45][46][47][48] With the gut microbiome playing such an important role in this disease, recent research is even focused on fecal transfer experiments as a therapeutic option. 49,50 In addition, potential treatments against colitis are being examined more thoroughly to determine what, if any, effects these possible therapeutics have on the gut microbiome. 51,52 In the current study, we were able to show that bacteria, such as those belonging to the Genus Ruminococcus, are increased during resveratrol treatment, which is consistent with animal studies and human fecal transplant experiments in which bacteria such as Ruminococcus and others were found to be anti-inflammatory, restoring and maintaining normal gastrointestinal tract function and integrity.…”

Section: Discussionmentioning

confidence: 99%

Resveratrol modulates the gut microbiota to prevent murine colitis development through induction of Tregs and suppression of Th17 cells

Alrafas

Busbee

Nagarkatti

et al. 2019

Journal of Leukocyte Biology

133

View full text Add to dashboard Cite

Inflammatory diseases of the gastrointestinal tract are often associated with microbial dysbiosis. Thus, dietary interactions with intestinal microbiota, to maintain homeostasis, play a crucial role in regulation of clinical disorders such as colitis. In the current study, we investigated if resveratrol, a polyphenol found in a variety of foods and beverages, would reverse microbial dysbiosis induced during colitis. Administration of resveratrol attenuated colonic inflammation and clinical symptoms in the murine model of 2,4,6‐trinitrobenzenesulfonic acid (TNBS)‐induced colitis. Resveratrol treatment in mice with colitis led to an increase in CD4+FOXP3+ and CD4+IL‐10+ T cells, and a decrease in CD4+IFN‐γ+ and CD4+IL‐17+ T cells. 16S rRNA gene sequencing to investigate alterations in the gut microbiota revealed that TNBS caused significant dysbiosis, which was reversed following resveratrol treatment. Analysis of cecal flush revealed that TNBS administration led to an increase in species such as Bacteroides acidifaciens, but decrease in species such as Ruminococcus gnavus and Akkermansia mucinphilia, as well as a decrease in SCFA i‐butyric acid. However, resveratrol treatment restored the gut bacteria back to homeostatic levels, and increased production of i‐butyric acid. Fecal transfer experiments confirmed the protective role of resveratrol‐induced microbiota against colitis inasmuch as such recipient mice were more resistant to TNBS‐colitis and exhibited polarization toward CD4+FOXP3+ T cells and decreases in CD4+IFN‐γ+ and CD4+IL‐17+ T cells. Collectively, these data demonstrate that resveratrol‐mediated attenuation of colitis results from reversal of microbial dysbiosis induced during colitis and such microbiota protect the host from colonic inflammation by inducing Tregs while suppressing inflammatory Th1/Th17 cells.

show abstract

Section: Discussionmentioning

confidence: 99%

Resveratrol modulates the gut microbiota to prevent murine colitis development through induction of Tregs and suppression of Th17 cells

Alrafas

Busbee

Nagarkatti

et al. 2019

Journal of Leukocyte Biology

133

View full text Add to dashboard Cite

show abstract

“…There is growing evidence that indicates the potential therapeutic role of FMT in patients with IBD. In this group of patients, most FMT studies were focused on the treatment of IBD and the treatment of CDI in IBD [14][15][16][17]. CMV is another infectious agent which may play a significant role in the natural course of IBD, especially in UC.…”

Section: Discussionmentioning

confidence: 99%

Faecal Microbiota Transfer – a new concept for treating cytomegalovirus colitis in children with ulcerative colitis

Karolewska-Bochenek

Łazowska-Przeorek

Grzesiowski³

et al. 2020

Ann Agric Environ Med.

View full text Add to dashboard Cite

show abstract

“…Articles were rejected if they focused on a specific immunocompromised population outside of HIV such as patients with Inflammatory Bowel Disease (IBD) 1 or patients with solid organ transplants(SOT). 2 These were rejected as they did not align with the etiology of the patient's immunocompromised state.…”

Section: Related Literaturementioning

confidence: 99%

Fecal microbiota therapy in recurrent and refractory clostridium difficile infections has been associated with positive results in immunocompromised patients

Applebach

2019

Clin. Res. Pract.

View full text Add to dashboard Cite

show abstract

Outcomes of Fecal Microbiota Transplantation for Clostridium difficile Infection in Patients with Inflammatory Bowel Disease

Abstract: Fecal microbiota transplantation provides a good alternative treatment option with high success rates for recurrent or refractory Clostridium difficile infection in patients with well-controlled IBD who fail standard antimicrobial therapy.

Cited by 33 publications

References 29 publications

Resveratrol modulates the gut microbiota to prevent murine colitis development through induction of Tregs and suppression of Th17 cells

Resveratrol modulates the gut microbiota to prevent murine colitis development through induction of Tregs and suppression of Th17 cells

Faecal Microbiota Transfer – a new concept for treating cytomegalovirus colitis in children with ulcerative colitis

Fecal microbiota therapy in recurrent and refractory clostridium difficile infections has been associated with positive results in immunocompromised patients

Contact Info

Product

Resources

About